Evolent Health Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Evolent Health stock has a consensus rating of "Buy" and an average price target of $5.88. The average 1-year stock price forecast is 31.25% higher than the current stock price, while the lowest is $3.00 (-33.04%) and the highest is $8.00 (+78.57%).

Price Target: $5.88 (+31.25%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$3.00	$5.88	$6.00	$8.00
Change	-33.04%	+31.25%	+33.93%	+78.57%

Analyst Ratings

The average analyst rating for Evolent Health stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	11	10	10	10	10	9
Buy	4	4	4	4	4	4
Hold	1	2	2	2	2	2
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	16	16	16	16	16	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jailendra Singh Truist Financial	Truist Financial	Buy Maintains $6 → $7	Buy	Maintains	$6 → $7	+56.25%	Jun 12, 2026
Ryan Daniels William Blair	William Blair	Buy Maintains n/a	Buy	Maintains	n/a	n/a	May 15, 2026
Daniel Grosslight Citi	Citi	Buy Maintains $4 → $5.5	Buy	Maintains	$4 → $5.5	+22.77%	May 15, 2026
Richard Close Canaccord Genuity	Canaccord Genuity	Buy Maintains $5 → $6	Buy	Maintains	$5 → $6	+33.93%	May 12, 2026
Charles Rhyee TD Cowen	TD Cowen	Buy Maintains $7 → $8	Buy	Maintains	$7 → $8	+78.57%	May 11, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

2.50B

from 1.88B

33.32%

from 1.88B

Revenue Next Year

2.95B

from 2.50B

18.04%

from 2.50B

EPS This Year

0.20

from 0.09

118.38%

from 0.09

EPS Next Year

0.38

from 0.20

95.84%

from 0.20

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	907.96M	1.35B	1.96B	2.55B	1.88B	2.50B
Revenue Growth	-1.80%	48.91%	45.26%	30.09%	-26.56%	33.32%
Gross Profit	250.41M	316.58M	460.47M	367.35M	399.88M	395.52M
Gross Margin	27.58%	23.42%	23.45%	14.38%	21.31%	15.81%
Operating Income	-17.41M	-19.88M	14.18M	23.94M	-4.44M	86.52M
Net Income	-37.60M	-19.16M	-113.04M	-61.62M	-534.51M	-78.49M
EPS	-	-	-	-	0.09	0.20
EPS Growth	-	-	-	-	-78.05%	118.38%
Forward PE	-	44.32	38.40	13.66	16.88	22.79
Free Cash Flow	93.58M	12.57M	162.10M	-48.00M	98.41M	-11.50M
No. Analysts	-	-	-	-	-	15

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	2.6B
Avg	2.5B
Low	2.4B

Revenue Growth

Revenue Growth	2026	2027	2028
High	39.2%
Avg	33.3%
Low	29.7%

EPS Forecast

EPS	2026	2027	2028
High	0.26
Avg	0.20
Low	0.13

EPS Growth

EPS Growth	2026	2027	2028
High	188.9%
Avg	118.4%
Low	44.4%